NuCana Revenue and Competitors
Estimated Revenue & Valuation
- NuCana's estimated annual revenue is currently $6.8M per year.
- NuCana's estimated revenue per employee is $126,296
- NuCana's current valuation is $148.2M. (January 2022)
Employee Data
- NuCana has 54 Employees.
NuCana's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | VP, Pharmacovigilance | Reveal Email/Phone |
3 | SVP Clinical & Medical Development | Reveal Email/Phone |
4 | Chief Financial Officer | Reveal Email/Phone |
5 | Director Regulatory Affairs | Reveal Email/Phone |
6 | Senior Project Director | Reveal Email/Phone |
7 | Clinical Trial Assistant | Reveal Email/Phone |
NuCana Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is NuCana?
NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our phosphoramidate chemistry technology to transform some of the most widely prescribed chemotherapy agents into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid tumours, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilising our proprietary ProTide technology, we are developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells.
keywords:N/A
N/A
Total Funding
54
Number of Employees
$6.8M
Revenue (est)
N/A
Employee Growth %
$148.2M
Valuation
N/A
Accelerator
NuCana News
NuCana posted earnings per share of ($0.26) in the same quarter last year, which indicates a positive year over year growth rate of 7.7%. The...
NuCana PLC is a biopharmaceutical company focused on improving treatment outcome for cancer patients by ProTide technology. Utilising...
NuCana PLC (NCNA) stock is lower by -81.05% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy.
Other Companies in Edinburgh
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $16M | 55 | 10% | N/A |
#2 | $14.4M | 55 | 2% | N/A |
#3 | $12M | 55 | -5% | N/A |
#4 | $7.4M | 57 | 6% | N/A |
#5 | $3.5M | 58 | 4% | N/A |